Low Dose Busulfan Is Associated with Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Gazourian Lee , Rogers Angela J , Igbanga Ruby , Weinhouse Gerald L , Soiffer Robert J , Antin Joseph H , Ritz Jerome , Ho Vincent T , Washko George R , Baron Rebecca M 
Published: October 2019

Abstract
Abstract 3128

Rationale:
Bronchiolitis obliterans syndrome (BOS) is the most common late non-infectious pulmonary complication following hematopoietic stem cell transplantation (HSCT). The prevalence is estimated to be between 5–10% after allogeneic HSCT with a significant increase in morbidity and mortality. We conducted a retrospective case control study to evaluate the associations between patients with BOS and those who did not develop airflow obstruction or symptoms.

Methods:
Between January 1st 2000 and June 30th 2010 all patients who underwent an allogeneic HSCT at the Dana-Farber Cancer Institute/Brigham and Women's Hospital (n=1854) were screened for the development of BOS, using a modified NIH diagnostic criteria. BOS was defined as 1) new onset airflow obstruction, FEV1/FVC ratio ≤0.7 and FEV1 <80% predicted; 2) irreversible obstruction defined as no response to bronchodilator per ATS criteria; 3) if airflow obstruction was noted prior to HSCT, a ≥15% decline in FEV1 from baseline; 4) BO confirmed by pathology irrespective of meeting the spirometric definition of BOS. We matched the BOS cases, based on date of HSCT (±90 days), with 2 groups of control subjects: 1) subjects who developed chronic graft vs. host disease (cGVHD) without BOS and 2) subjects who developed neither cGVHD nor BOS. Comparisons between BOS subjects and controls were conducted using t-test or Fisher's exact tests. We also performed a multivariate regression analysis predicting the development of BOS; all variables with a p <0.1 on univariate analysis were included in the model. All statistical analyses were performed using R.

Results:
We identified 89 subjects meeting our diagnostic criteria for BOS with a prevalence of 4.8%. The median time from transplantation to meeting criteria for BOS was 491 days (range: 48–2067). Univariate analysis demonstrated that BOS was significantly associated with previously reported risk factors including age, pre-transplantation PFT's, high risk disease, source of peripheral blood stem cells, unrelated donor, history of respiratory infection prior to day 100, and busulfan based conditioning regimens. (all p<0.05, table 1). Upon further stratification of regimens, univariate analysis demonstrated that reduced intensity conditioning busulfan was associated with the development of BOS (p<0.001). After analyzing our univariate associations in a multivariate model, busulfan-based conditioning and unrelated donors were independent factors associated with BOS (p <0.001), while, ATG use conferred lower odds of BOS (p<0.001).

Conclusion:
Our findings extend those from prior reports of risk factors associated with BOS. Our results demonstrate that busulfan, even when used at lower doses in reduced intensity conditioning transplantation, confers an increased risk for BOS. Future studies in prospective cohorts will be important to confirm these findings.

Disclosures:
No relevant conflicts of interest to declare.